The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation

Medicina (Kaunas). 2024 Mar 29;60(4):563. doi: 10.3390/medicina60040563.

Abstract

The gastrointestinal tract is inhabited by the gut microbiota. The main phyla are Firmicutes and Bacteroidetes. In non-alcoholic fatty liver disease, now renamed metabolic dysfunction-associated fatty liver disease (MAFLD), an alteration in Firmicutes and Bacteroidetes abundance promotes its pathogenesis and evolution into non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. For this reason, early treatment is necessary to counteract its progression. The aim of the present narrative review is to evaluate the different therapeutic approaches to MAFLD. The most important treatment for MAFLD is lifestyle changes. In this regard, the Mediterranean diet could be considered the gold standard in the prevention and treatment of MAFLD. In contrast, a Western diet should be discouraged. Probiotics and fecal microbiota transplantation seem to be valid, safe, and effective alternatives for MAFLD treatment. However, more studies with a longer follow-up and with a larger cohort of patients are needed to underline the more effective approaches to contrasting MAFLD.

Keywords: Mediterranean diet; gut–liver axis; leaky gut; probiotics; steatosis.

Publication types

  • Review

MeSH terms

  • Diet, Mediterranean*
  • Fecal Microbiota Transplantation* / methods
  • Gastrointestinal Microbiome / physiology
  • Humans
  • Non-alcoholic Fatty Liver Disease* / microbiology
  • Non-alcoholic Fatty Liver Disease* / therapy
  • Probiotics / administration & dosage
  • Probiotics / therapeutic use

Grants and funding

This research received no external funding.